EUCTR2007-001548-36-DE进行中（未招募）1 期
asale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler.- bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -Nasal Inhalation of Dornase alfa (Pulmozyme) in Patients with Cystic Fibrosis and Chronic Rhinosinusitis - pulmozyme-nasal-cf
niversity of Jena0 个研究点目标入组 16 人开始时间: 2009年7月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject has a confirmed diagnosis of cystic fibrosis based on:
- •3 positive sweat chloride tests and/or genetic characterisation.
- •2. Subject is 5 years of age or older.
- •3. Subject has chronic or recurrent rhinosinusitic disorders.
- •4. Subject is able to comply with the Inhalation procedures scheduled in the protocol.
- •5. Subject is able to comply with the nasal lavage procedures scheduled in the protocol.
- •6. Therapy is completely possible without any restrictions.
- •5. Women of childbearing potential are only included into the study, if they are using an effective method of birth control during the protocol (e.g. implants, combined oral contraceptives, injectables, some IUDs, sexual abstinence or vasectomised partner).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has a critical condition defined as:
- •FEV1 < 30% and / or
- •SaO2 < 93% without O2-substitution; need of O2-substitution
- •2. Subject had an ENT surgery within 6 months prior to study
- •3. Subject shows signs of nasal bleeding
- •4. Subject has an ear drum perforation
- •5. Subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with need of additional systemic antibiotic therapy
- •6. Subject has a new therapy with nasal topic steroids during treatment interval
- •7. Subject has a new systemic steroid therapy
- •8. Subject is unlikely to comply with the procedures scheduled in the protocol
- •9. Subject has a known allergic reaction to the medication
- •10. Subject is pregnant or breastfeeding
- •11.Patient participates in another clinical trial within 30 days prior to study entry or 30 days after end of the study.
研究者
相似试验
进行中（未招募）
不适用
Determination of the pharmacokinetics of inhaled mannitol after single and multiple dosing in cystic fibrosis patientsCystic FibrosisEUCTR2008-008228-34-GBPharmaxis Ltd18
进行中（未招募）
1 期
Assessment of meropenem concentrations in lungs in patients with postoperative pneumonia.EUCTR2016-002796-10-ESConsorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)
尚未招募
不适用
Investigation on exhalation gas in patients undergoing cardiac surgery or thoracic aortic surgery using cardiopulmonary bypasscardiac surgery, thoracic aortic surgeryJPRN-UMIN000036070Division of Anesthesiology and Critical Care Medicin, Tottori University20
招募中
3 期
Evaluation of the efficacy and safety of inhaled magnesium sulfate in combination with standard treatment in Covid-19 patientsCovid-19.COVID-19, virus identifiedU07.1IRCT20191211045691N1ational Research Institute of Tuberculosis and Lung Diseases(NRITLD), Masih Daneshvari Hospital100
招募中
不适用
Airway oxygen concentration with high flow nasal oxygeACTRN12618001256268Christchurch public hospital10